BACKGROUND This study was designed to investigate the clinical efficacy and safety of Gamma Knife®combined with transarterial chemoembolization(TACE)and immunotherapy in the treatment of primary liver cancer.AIM ...BACKGROUND This study was designed to investigate the clinical efficacy and safety of Gamma Knife®combined with transarterial chemoembolization(TACE)and immunotherapy in the treatment of primary liver cancer.AIM To investigate the clinical efficacy and safety of Gamma Knife®combined with TACE and immune-targeted therapy in the treatment of primary liver cancer.METHODS Clinical data from 51 patients with primary liver cancer admitted to our hospital between May 2018 and October 2022 were retrospectively collected.All patients underwent Gamma Knife®treatment combined with TACE and immunotherapy.The clinical efficacy,changes in liver function,overall survival(OS),and progression-free survival(PFS)of patients with different treatment responses were evaluated,and adverse reactions were recorded.RESULTS The last follow-up for this study was conducted on October 31,2023.Clinical evaluation of the 51 patients with primary liver cancer revealed a partial response(PR)in 27 patients,accounting for 52.94%(27/51);stable disease(SD)in 16 patients,accounting for 31.37%(16/51);and progressive disease(PD)in 8 patients,accounting for 15.69%(8/51).The objective response rate was 52.94%,and the disease control rate was 84.31%.Alanine aminotransferase,aspartate aminotransferase,lactate dehydrogenase,and alpha-fetoprotein isoform levels decreased after treatment compared with pretreatment(all P=0.000).The median OS was 26 months[95%confidence interval(95%CI):19.946-32.054]in the PR group and 19 months(95%CI:14.156-23.125)in the SD+PD group,with a statistically significant difference(P=0.015).The median PFS was 20 months(95%CI:18.441-34.559)in the PR group and 12 months(95%CI:8.745-13.425)in the SD+PD group,with a statistically significant difference(P=0.002).Common adverse reactions during treatment included nausea and vomiting(39.22%),thrombocytopenia(27.45%),and leukopenia(25.49%),with no treatment-related deaths reported.CONCLUSION Gamma Knife®combined with TACE and immune-targeted therapy is safe and effective in the treatment of primary liver cancer and has a good effect on improving the clinical benefit rate and liver function of patients.展开更多
The 21^(st) century has started with several innovations in the medical sciences,with wide applications in health care management.This development has taken in the field of medicines(newer drugs/molecules),various too...The 21^(st) century has started with several innovations in the medical sciences,with wide applications in health care management.This development has taken in the field of medicines(newer drugs/molecules),various tools and technology which has completely changed the patient management including abdominal surgery.Surgery for abdominal diseases has moved from maximally invasive to minimally invasive(laparoscopic and robotic)surgery.Some of the newer medicines have its impact on need for surgical intervention.This article focuses on the development of these emerging molecules,tools,and technology and their impact on present surgical form and its future effects on the surgical intervention in gastroenterological diseases.展开更多
目的两种阑尾插管方法在内镜逆行阑尾炎治疗术中的应用比较。方法100例急性非复杂性阑尾炎患者随机分为弓刀组(50例)与导管组(50例),弓刀组采用乳头括约肌切开刀配合导丝阑尾插管,辅助内镜逆行阑尾炎治疗术,导管组采用造影导管配合导丝...目的两种阑尾插管方法在内镜逆行阑尾炎治疗术中的应用比较。方法100例急性非复杂性阑尾炎患者随机分为弓刀组(50例)与导管组(50例),弓刀组采用乳头括约肌切开刀配合导丝阑尾插管,辅助内镜逆行阑尾炎治疗术,导管组采用造影导管配合导丝阑尾插管,辅助内镜逆行阑尾炎治疗术。比较两组阑尾插管成功率、阑尾插管时间、手术时间、住院天数、腹痛消失时间、麦氏点压痛消失时间、白细胞复常时间、中性粒细胞百分比复常时间、阑尾炎复发率及手术并发症发生率。结果弓刀组阑尾插管时间短于导管组阑尾插管时间[6.00(4.15~7.45)min vs 8.65(6.08~11.23)min,P<0.001],弓刀组手术时间短于导管组手术时间[(47.51±10.70)min vs(55.96±12.21)min,P<0.001]。弓刀组阑尾插管成功率100%高于导管组阑尾插管成功率88%(P<0.05)。两组住院天数、腹痛消失时间、麦氏点压痛消失时间、白细胞复常时间、中性粒细胞百分比复常时间、阑尾炎复发率及手术并发症发生率比较无差异。结论乳头括约肌切开刀辅助阑尾插管能提高内镜逆行阑尾炎治疗术阑尾插管成功率、缩短阑尾插管时间及手术时间,不增加手术并发症,安全有效,值得临床推广。展开更多
目的:探讨J型针刀通过PACAP-cAMP-PKA信号通路改善脊髓损伤后神经源性膀胱大鼠逼尿肌的作用机制。方法:36只SD雄性大鼠随机分为6组:空白组、假手术组、模型组、J型针刀治疗组、治疗+Bupivacaine抑制剂组、治疗+H-89抑制剂组,各6只。采...目的:探讨J型针刀通过PACAP-cAMP-PKA信号通路改善脊髓损伤后神经源性膀胱大鼠逼尿肌的作用机制。方法:36只SD雄性大鼠随机分为6组:空白组、假手术组、模型组、J型针刀治疗组、治疗+Bupivacaine抑制剂组、治疗+H-89抑制剂组,各6只。采用脊髓横断法制作神经源性膀胱模型。空白组为正常SD大鼠;假手术组为切开相关部位组织,无脊髓切断;其余4组予以手术脊髓切断造模。J型针刀治疗组造模后第19天予J型针刀针刺大鼠次髎穴,2 d 1次,共治疗7次。干预结束后各组行HE染色观察膀胱逼尿肌组织形态变化,Elisa检测膀胱逼尿肌组织中c AMP、PKA含量,免疫组化检测膀胱逼尿肌组织中PACAP38蛋白表达,Western blot检测膀胱逼尿肌组织中PKA、p-MLC蛋白表达。结果:HE染色结果显示,与空白组相比,模型组中膀胱逼尿肌组织严重坏死,可见大量炎症细胞浸润;与模型组相比,J型针刀治疗组、治疗+Bupivacaine抑制剂组及治疗+H-89抑制剂组均有不同程度坏死组织修复情况。免疫组化检测PACAP38蛋白表达在模型组中表达量最低,针刀治疗之后,PACAP38表达量均不同程度上调;与J型针刀治疗组相比,治疗+Bupivacaine抑制剂组及治疗+H-89抑制剂组PACAP38蛋白表达均不同程度下调(P<0.05),但高于模型组(P<0.05)。Elisa检测结果显示,cAMP、PKA表达量模型组显著下调(P<0.05),J型针刀治疗组与模型组比显著上调(P<0.05),治疗+Bupivacaine抑制剂组及治疗+H-89抑制剂组比无显著差异(P>0.05)。WB结果显示:与空白组相比,模型组PKA、p-MLC蛋白表达上调;针刀治疗组表达量下调,其中PKA蛋白表达有显著性(P<0.05),p-MLC蛋白表达无显著性(P>0.05)。与J型针刀治疗组比,PKA蛋白表达量在治疗+Bupivacaine抑制剂组及治疗+H-89抑制剂组中无显著差异(P>0.05),p-MLC蛋白表达量显著下降(P<0.05)。结论:J型针刀针刺次髎穴可改善脊髓损伤后神经源性膀胱大鼠膀胱功能,其机制与J型针刀上调膀胱逼尿肌中PACAP38、cAMP、PKA表达,激活PACAP-cAMP-PKA信号通路,从而促进逼尿肌舒张有关。展开更多
文摘BACKGROUND This study was designed to investigate the clinical efficacy and safety of Gamma Knife®combined with transarterial chemoembolization(TACE)and immunotherapy in the treatment of primary liver cancer.AIM To investigate the clinical efficacy and safety of Gamma Knife®combined with TACE and immune-targeted therapy in the treatment of primary liver cancer.METHODS Clinical data from 51 patients with primary liver cancer admitted to our hospital between May 2018 and October 2022 were retrospectively collected.All patients underwent Gamma Knife®treatment combined with TACE and immunotherapy.The clinical efficacy,changes in liver function,overall survival(OS),and progression-free survival(PFS)of patients with different treatment responses were evaluated,and adverse reactions were recorded.RESULTS The last follow-up for this study was conducted on October 31,2023.Clinical evaluation of the 51 patients with primary liver cancer revealed a partial response(PR)in 27 patients,accounting for 52.94%(27/51);stable disease(SD)in 16 patients,accounting for 31.37%(16/51);and progressive disease(PD)in 8 patients,accounting for 15.69%(8/51).The objective response rate was 52.94%,and the disease control rate was 84.31%.Alanine aminotransferase,aspartate aminotransferase,lactate dehydrogenase,and alpha-fetoprotein isoform levels decreased after treatment compared with pretreatment(all P=0.000).The median OS was 26 months[95%confidence interval(95%CI):19.946-32.054]in the PR group and 19 months(95%CI:14.156-23.125)in the SD+PD group,with a statistically significant difference(P=0.015).The median PFS was 20 months(95%CI:18.441-34.559)in the PR group and 12 months(95%CI:8.745-13.425)in the SD+PD group,with a statistically significant difference(P=0.002).Common adverse reactions during treatment included nausea and vomiting(39.22%),thrombocytopenia(27.45%),and leukopenia(25.49%),with no treatment-related deaths reported.CONCLUSION Gamma Knife®combined with TACE and immune-targeted therapy is safe and effective in the treatment of primary liver cancer and has a good effect on improving the clinical benefit rate and liver function of patients.
文摘The 21^(st) century has started with several innovations in the medical sciences,with wide applications in health care management.This development has taken in the field of medicines(newer drugs/molecules),various tools and technology which has completely changed the patient management including abdominal surgery.Surgery for abdominal diseases has moved from maximally invasive to minimally invasive(laparoscopic and robotic)surgery.Some of the newer medicines have its impact on need for surgical intervention.This article focuses on the development of these emerging molecules,tools,and technology and their impact on present surgical form and its future effects on the surgical intervention in gastroenterological diseases.
文摘目的两种阑尾插管方法在内镜逆行阑尾炎治疗术中的应用比较。方法100例急性非复杂性阑尾炎患者随机分为弓刀组(50例)与导管组(50例),弓刀组采用乳头括约肌切开刀配合导丝阑尾插管,辅助内镜逆行阑尾炎治疗术,导管组采用造影导管配合导丝阑尾插管,辅助内镜逆行阑尾炎治疗术。比较两组阑尾插管成功率、阑尾插管时间、手术时间、住院天数、腹痛消失时间、麦氏点压痛消失时间、白细胞复常时间、中性粒细胞百分比复常时间、阑尾炎复发率及手术并发症发生率。结果弓刀组阑尾插管时间短于导管组阑尾插管时间[6.00(4.15~7.45)min vs 8.65(6.08~11.23)min,P<0.001],弓刀组手术时间短于导管组手术时间[(47.51±10.70)min vs(55.96±12.21)min,P<0.001]。弓刀组阑尾插管成功率100%高于导管组阑尾插管成功率88%(P<0.05)。两组住院天数、腹痛消失时间、麦氏点压痛消失时间、白细胞复常时间、中性粒细胞百分比复常时间、阑尾炎复发率及手术并发症发生率比较无差异。结论乳头括约肌切开刀辅助阑尾插管能提高内镜逆行阑尾炎治疗术阑尾插管成功率、缩短阑尾插管时间及手术时间,不增加手术并发症,安全有效,值得临床推广。
文摘目的:探讨J型针刀通过PACAP-cAMP-PKA信号通路改善脊髓损伤后神经源性膀胱大鼠逼尿肌的作用机制。方法:36只SD雄性大鼠随机分为6组:空白组、假手术组、模型组、J型针刀治疗组、治疗+Bupivacaine抑制剂组、治疗+H-89抑制剂组,各6只。采用脊髓横断法制作神经源性膀胱模型。空白组为正常SD大鼠;假手术组为切开相关部位组织,无脊髓切断;其余4组予以手术脊髓切断造模。J型针刀治疗组造模后第19天予J型针刀针刺大鼠次髎穴,2 d 1次,共治疗7次。干预结束后各组行HE染色观察膀胱逼尿肌组织形态变化,Elisa检测膀胱逼尿肌组织中c AMP、PKA含量,免疫组化检测膀胱逼尿肌组织中PACAP38蛋白表达,Western blot检测膀胱逼尿肌组织中PKA、p-MLC蛋白表达。结果:HE染色结果显示,与空白组相比,模型组中膀胱逼尿肌组织严重坏死,可见大量炎症细胞浸润;与模型组相比,J型针刀治疗组、治疗+Bupivacaine抑制剂组及治疗+H-89抑制剂组均有不同程度坏死组织修复情况。免疫组化检测PACAP38蛋白表达在模型组中表达量最低,针刀治疗之后,PACAP38表达量均不同程度上调;与J型针刀治疗组相比,治疗+Bupivacaine抑制剂组及治疗+H-89抑制剂组PACAP38蛋白表达均不同程度下调(P<0.05),但高于模型组(P<0.05)。Elisa检测结果显示,cAMP、PKA表达量模型组显著下调(P<0.05),J型针刀治疗组与模型组比显著上调(P<0.05),治疗+Bupivacaine抑制剂组及治疗+H-89抑制剂组比无显著差异(P>0.05)。WB结果显示:与空白组相比,模型组PKA、p-MLC蛋白表达上调;针刀治疗组表达量下调,其中PKA蛋白表达有显著性(P<0.05),p-MLC蛋白表达无显著性(P>0.05)。与J型针刀治疗组比,PKA蛋白表达量在治疗+Bupivacaine抑制剂组及治疗+H-89抑制剂组中无显著差异(P>0.05),p-MLC蛋白表达量显著下降(P<0.05)。结论:J型针刀针刺次髎穴可改善脊髓损伤后神经源性膀胱大鼠膀胱功能,其机制与J型针刀上调膀胱逼尿肌中PACAP38、cAMP、PKA表达,激活PACAP-cAMP-PKA信号通路,从而促进逼尿肌舒张有关。
